deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 7-arm NCT02715284

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (GARNET)

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Sponsor: Tesaro, Inc.

Conditions Neoplasms
Interventions Dostarlimab
Updated 28 times since 2017 Last updated: Jan 9, 2026 Started: Mar 7, 2016 Primary completion: May 18, 2026 Completion: Jan 25, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02715284, this PHASE1 trial focuses on Neoplasms and remains ongoing. Sponsored by Tesaro, Inc., it has been updated 28 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Dec 2017 · 4 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~May 2019 · 7 months · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Feb 2020 · 5 months · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Dec 2022 · 7 months · monthly snapshot~Dec 2022 – ~Sep 2023 · 9 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

28 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Nov 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Sep 2025 — Nov 2025 [monthly]

    Recruiting PHASE1

  4. Apr 2025 — Sep 2025 [monthly]

    Recruiting PHASE1

  5. Sep 2024 — Apr 2025 [monthly]

    Recruiting PHASE1

▶ Show 23 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  2. Sep 2023 — Jul 2024 [monthly]

    Recruiting PHASE1

  3. Dec 2022 — Sep 2023 [monthly]

    Recruiting PHASE1

  4. May 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

  5. Mar 2022 — May 2022 [monthly]

    Recruiting PHASE1

  6. Dec 2021 — Mar 2022 [monthly]

    Recruiting PHASE1

  7. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE1

  8. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  9. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE1

  10. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  11. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE1

  12. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE1

  13. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE1

  14. Feb 2020 — Apr 2020 [monthly]

    Recruiting PHASE1

  15. Sep 2019 — Feb 2020 [monthly]

    Recruiting PHASE1

  16. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE1

  17. May 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

  18. Oct 2018 — May 2019 [monthly]

    Recruiting PHASE1

  19. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  20. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  21. Aug 2017 — Dec 2017 [monthly]

    Recruiting PHASE1

  22. Feb 2017 — Aug 2017 [monthly]

    Recruiting PHASE1

  23. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Tesaro, Inc.
Data source: Tesaro, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom , Albany, United States , Augusta, United States , Baltimore, United States , Barcelona, Spain , Birmingham, United States , Boston, United States , Brooklyn, United States , Caen, France , Calgary, Canada and 74 more locations